$322 Million is the total value of Nan Fung Group Holdings Ltd's 24 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EAR | New | EARGO INC | $115,209,000 | – | 2,886,724 | +100.0% | 35.80% | – |
| NFH | New | NEW FRONTIER HEALTH CORP | $93,270,000 | – | 8,350,000 | +100.0% | 28.98% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $26,766,000 | – | 234,811 | +100.0% | 8.32% | – |
| HRMY | New | HARMONY BIOSCIENCES HLDGS IN | $21,701,000 | – | 768,708 | +100.0% | 6.74% | – |
| BOLT | New | BOLT BIOTHERAPEUTICS INC | $18,041,000 | – | 1,166,952 | +100.0% | 5.60% | – |
| BEAM | New | BEAM THERAPEUTICS INC | $6,263,000 | – | 48,660 | +100.0% | 1.95% | – |
| GRTX | New | GALERA THERAPEUTICS INC | $6,028,000 | – | 613,223 | +100.0% | 1.87% | – |
| NVTA | New | INVITAE CORP | $4,880,000 | – | 144,667 | +100.0% | 1.52% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $3,685,000 | – | 197,880 | +100.0% | 1.14% | – |
| NFHWS | New | NEW FRONTIER HEALTH CORP*w exp 11/30/202 | $3,666,000 | – | 1,580,000 | +100.0% | 1.14% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $3,246,000 | – | 68,663 | +100.0% | 1.01% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $2,550,000 | – | 130,979 | +100.0% | 0.79% | – |
| ARDX | New | ARDELYX INC | $2,465,000 | – | 325,233 | +100.0% | 0.77% | – |
| EXAS | New | EXACT SCIENCES CORP | $2,171,000 | – | 17,464 | +100.0% | 0.68% | – |
| ALXO | New | ALX ONCOLOGY HLDGS INC | $1,911,000 | – | 34,950 | +100.0% | 0.59% | – |
| OTIC | New | OTONOMY INC | $1,898,000 | – | 851,000 | +100.0% | 0.59% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $1,886,000 | – | 78,720 | +100.0% | 0.59% | – |
| DBVT | New | DBV TECHNOLOGIES S Asponsored adr | $1,559,000 | – | 285,500 | +100.0% | 0.48% | – |
| RUBY | New | RUBIUS THERAPEUTICS INC | $1,386,000 | – | 56,768 | +100.0% | 0.43% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $1,170,000 | – | 8,265 | +100.0% | 0.36% | – |
| EXEL | New | EXELIXIS INC | $1,170,000 | – | 64,200 | +100.0% | 0.36% | – |
| FLNT | New | FLUENT INC | $571,000 | – | 194,799 | +100.0% | 0.18% | – |
| SYBX | New | SYNLOGIC INC | $267,000 | – | 68,634 | +100.0% | 0.08% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $86,000 | – | 3,470 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-09-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 10 | Q3 2023 | 34.7% |
| HARMONY BIOSCIENCES HLDGS IN | 10 | Q3 2023 | 21.3% |
| XENON PHARMACEUTICALS INC | 10 | Q3 2023 | 3.1% |
| BOLT BIOTHERAPEUTICS INC | 10 | Q3 2023 | 5.6% |
| GALERA THERAPEUTICS INC | 10 | Q3 2023 | 1.9% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q3 2023 | 1.8% |
| EXELIXIS INC | 10 | Q3 2023 | 1.1% |
| DBV TECHNOLOGIES S A | 10 | Q3 2023 | 0.6% |
| ALX ONCOLOGY HLDGS INC | 10 | Q3 2023 | 1.0% |
| ILLUMINA INC | 9 | Q3 2023 | 21.5% |
View Nan Fung Group Holdings Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eargo, Inc. | December 16, 2022 | 2,958,099 | 0.7% |
| Stealth BioTherapeutics Corp | January 09, 2020 | 20,240,817 | 4.8% |
| New Frontier Health Corp | January 02, 2020 | 9,650,000 | 7.3% |
View Nan Fung Group Holdings Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-16 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Nan Fung Group Holdings Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.